Insider Trading Alert - GPN, UHS And ISIS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Aug. 1, 2014, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $28,592,784.28.

Highlighted Stocks Traded by Insiders:

Global Payments (GPN) - FREE Research Report

Jacobs William I, who is Director at Global Payments, sold 600 shares at $69.02 on Aug. 1, 2014. Following this transaction, the Director owned 32,165 shares meaning that the stake was reduced by 1.83% with the 600-share transaction.

The shares most recently traded at $69.19, up $0.17, or 0.25% since the insider transaction. Historical insider transactions for Global Payments go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 600
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 3,200
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 10,858

The average volume for Global Payments has been 617,600 shares per day over the past 30 days. Global Payments has a market cap of $4.7 billion and is part of the services sector and diversified services industry. Shares are up 6.59% year-to-date as of the close of trading on Friday.

Global Payments Inc. provides electronic payments transaction processing services worldwide. The company serves as the processing intermediary between the merchant, the credit and debit networks, and the financial institutions that issue cards. The stock currently has a dividend yield of 0.12%. The company has a P/E ratio of 20.6. Currently, there are 6 analysts who rate Global Payments a buy, 2 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPN - FREE

TheStreet Quant Ratings rates Global Payments as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Global Payments Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Universal Health Services (UHS) - FREE Research Report

Hotz Robert H, who is Director at Universal Health Services, sold 18,804 shares at $106.95 on Aug. 1, 2014. Following this transaction, the Director owned 40,411 shares meaning that the stake was reduced by 31.76% with the 18,804-share transaction.

Gibbs Lawrence S., who is Director at Universal Health Services, sold 1,000 shares at $107.12 on Aug. 1, 2014. Following this transaction, the Director owned 1,393 shares meaning that the stake was reduced by 41.79% with the 1,000-share transaction.

The shares most recently traded at $105.79, down $1.33, or 1.25% since the insider transaction. Historical insider transactions for Universal Health Services go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 10,000

The average volume for Universal Health Services has been 810,300 shares per day over the past 30 days. Universal Health Services has a market cap of $9.8 billion and is part of the health care sector and health services industry. Shares are up 29.67% year-to-date as of the close of trading on Friday.

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The stock currently has a dividend yield of 0.38%. The company has a P/E ratio of 18.9. Currently, there are 12 analysts who rate Universal Health Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UHS - FREE

TheStreet Quant Ratings rates Universal Health Services as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Universal Health Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Isis Pharmaceuticals (ISIS) - FREE Research Report

Monia Brett P, who is SVP, Antisense Drug Discovery at Isis Pharmaceuticals, sold 79 shares at $31.50 on Aug. 1, 2014. Following this transaction, the SVP, Antisense Drug Discovery owned 1,813 shares meaning that the stake was reduced by 4.18% with the 79-share transaction.

The shares most recently traded at $30.55, down $0.95, or 3.11% since the insider transaction. Historical insider transactions for Isis Pharmaceuticals go as follows:

  • 4-Week # shares sold: 164
  • 12-Week # shares sold: 164
  • 24-Week # shares sold: 164

The average volume for Isis Pharmaceuticals has been 2.5 million shares per day over the past 30 days. Isis Pharmaceuticals has a market cap of $3.6 billion and is part of the health care sector and drugs industry. Shares are down 23.69% year-to-date as of the close of trading on Friday.

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. Currently, there are 4 analysts who rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ISIS - FREE

TheStreet Quant Ratings rates Isis Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Isis Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Activision Blizzard, Xilinx, Priceline Group: 'Mad Money' Lightning Round

Activision Blizzard, Xilinx, Priceline Group: 'Mad Money' Lightning Round

Buy on Weakness: Cramer's 'Mad Money' Recap (Thursday 10/19/17)

Buy on Weakness: Cramer's 'Mad Money' Recap (Thursday 10/19/17)

Cramer: Here Are the Ideal Stocks Now

Cramer: Here Are the Ideal Stocks Now

The Amazon Effect Extends to Payments Industry With Vantiv-Worldpay Deal

The Amazon Effect Extends to Payments Industry With Vantiv-Worldpay Deal